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Letters to the editor
Please submit letters for the editor’s consideration within 
three weeks of receipt of Clinical Medicine. Letters should 
ideally be limited to 350 words, and sent by email to: 
clinicalmedicine@rcplondon.ac.uk
Brucella and Coxiella; if you don't look, you don't ﬁ nd
We thank Dr Giles Youngs and Dr Peter Stride for 
highlighting a factual error in an article on Brucella and 
Coxiella (Clin Med 2015;15:91–2). The authors confi rm that 
the statement ‘Coxiella burnetii is the cause of Q fever, a term 
fi rst used in 1983 during the investigation of a cluster of 
febrile Australian meat workers’ should in fact read, ‘Coxiella 
burnetii is the cause of Q fever, a term fi rst used in 1937 
during the investigation of a cluster of febrile Australian meat 
workers’. 
Myasthenia gravis as a ‘stroke mimic’
Editor – Shaik and colleagues (Clin Med December 2014 
pp 640–2) elegantly highlight the importance of an accurate 
history in the diagnosis of myasthenia gravis (MG) and 
offer important differentials of the condition. However, by 
not explicitly discussing the possible role of iatrogeny as a 
contributing factor for the ‘patient’s rapid deterioration,’ an 
important learning point may have been missed.
In the case, the patient’s condition appears to have 
deteriorated further after he was administered gentamicin 
(for possible aspiration pneumonia) and verapamil (for atrial 
fi brillation). Both of these drugs can affect neuromuscular 
transmission and result in clinically signifi cant weakness 
in patients with MG.1,2 Indeed the British National 
Formulary registers all aminoglycosides along with two other 
antibiotics, telithromycin and colistin, as a contraindication 
in MG. Other agents that could conceivably be administered 
to critically unwell patients but should be avoided in MG if 
possible include: high dose intravenous magnesium (pre-
eclampsia or severe asthma), intravenous lignocaine for 
ventricular arrhythmias (safe as a local anaesthetic) and 
neuromuscular blocking agents. 4 If these drugs are given then 
the patient should be monitored in a high-dependency area, 
where they are able to receive ventilatory support if acutely 
needed.
It is not necessary to recall all the medications that ought to 
be used with caution in patients with MG as these are readily 
available online.3,4 However, we hope this letter will serve to 
remind those that might be involved in the care of patients 
with MG to perform a thorough risk benefi t analysis before 
starting new drugs and have a process for actively monitoring 
them for early signs of deterioration. ■
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Response
Editor – The comments by Patel et al are very welcome as they 
make an important point that certain drugs can exacerbate 
myasthenia gravis.
In our case, the initial clinical deterioration occurred prior 
to the administration of gentamicin and verapamil. When the 
patient deteriorated he was transferred to the intensive care 
unit, which facilitated close monitoring, and indeed, ventilatory 
support. 
It should also be borne in mind that at the time of 
administration of these drugs, the diagnosis of myasthenia 
gravis had not been confi rmed. Nonetheless, caution 
certainly needs to be exercised with the administration of 
drugs which have the potential to exacerbate myasthenic 
weakness, even when the diagnosis is suspected on clinical 
grounds alone.
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